Compare FULC & HIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULC | HIO |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.4M | 335.7M |
| IPO Year | 2019 | N/A |
| Metric | FULC | HIO |
|---|---|---|
| Price | $3.83 | $3.45 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $16.38 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 301.5K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.33% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $3.46 |
| 52 Week High | $15.74 | $4.05 |
| Indicator | FULC | HIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 40.81 |
| Support Level | $3.44 | $3.47 |
| Resistance Level | $3.92 | $3.68 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 28.13 | 27.27 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.